RRML - An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- February 2024 -
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 17
Recomandarea comună EFLM-COLA... 13
Approaching Risk Management in... 12
Identification of shared hub g... 12
Challenges in prophylactic the... 12
Monocyte to high-density lipop... 9
Atellica CH 930 chemistry anal... 8
Understanding the key differen... 7
Clinical application value of ... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 27(1)/2019 DOI:10.2478/rrlm-2019-0003

Research article

An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid

Muhammet Murat Celik, Nizami Duran

Correspondence should be addressed to: Nizami Duran


Aim: The aim of this study was to investigate the in-vitro efficacy of Glycyrrhetinic acid against Helicobacter pylori (H. pylori) strains, as compared with conventional antibacterial agents. Methods: A total of 41 H. pylori isolates were used, 6 of which were of standard strains (NCTC 1637), 8 of which were drug-sensitive, and 27 were resistant to drugs isolates. Clarithromycin and metronidazole resistance in all strains of H. pylori were determined by the Epsilometer test (E-test) method. MIC study was performed by using microdilution broth method. Results: Glycyrrhetinic acid was found to be effective against H. pylori NCTC 1637 in doses of 12.0±4.38 µg/mL, while the MIC value of clinical H. pylori isolates susceptible to antimicrobials was 20.8±10.11 µg/ml. It was found that the MIC values for antimicrobial-sensitive clinical H. pylori isolates was higher when compared with H. pylori NCTC 1637 strains. The MIC values of the standard antimicrobial agents against drug-resistant H. pylori strains were higher than H. pylori NCTC 1637 strains and drug-sensitive H. pylori strains. The MIC value was found to be 14.22±7.77 µg/ml for metronidazole, 3.89±1.90 µg/ml for clarithromycin, 2.33±1.0 µg/ml for amoxicillin, 2.44±0.88 µg/ml for levofloxacin and 4.89±2.47 µg/ml for tetracycline, whereas the MIC value of Glycyrrhetinic acid was 26.67±8.0 µg/ml in metronidazole-resistant H. pylori isolates. Besides, MIC values of the antimicrobials and 18ß-Glycyrrhetinic acid among the strains resistant to clarithromycin were as follows: 3.25±2.12 µg/ml for metronidazole, 9.71±4.54 µg/ml for clarithromycin, 2.06±1.32 µg/ml for amoxicillin, 3.88±4.22 µg/ml for levofloaxacin and 3.25±1.04 µg/mL for tetracycline and 22.0±11.11 µg/ml for Glycyrrhetinic acid. Conclusion: Glycyrrhetinic acid had significant antimicrobial activity against H. pylori strains. Although further in-vivo studies are needed on antimicrobial activity of Glycyrrhetinic acid, increased resistance to drugs currently used in treatment suggests that Glycyrrhetinic acid may be a potential agent for the treatment of H. pylori.

Keywords: Glycyrrhetinic acid, Helicobacter pylori, drug, resistance, metronidazole, clarithromycin

Received: 17.6.2018
Accepted: 3.11.2018
Published: 6.1.2019

  PDF Download full text PDF
(461 KB)
How to cite
Celik MM, Duran N. An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid. Rev Romana Med Lab. 2019;27(1):63-71. DOI:10.2478/rrlm-2019-0003